Tata Capital Healthcare Fund has advanced $4 million (approx Rs 25.6 crore) to Brinton Pharmaceuticals, one of the fastest growing pharmaceutical companies providing healthcare products and services for various therapeutic segments.
Brinton, a Pune basd company, at present mainly caters to dermatology and cosmeceuticals therapeutic segments in the Indian pharma market which is growing at a CAGR of 15%.
While speaking with Economic Times, Rahul Darda, managing director of Brinton Pharma said “Our plan is to enter into paediatric and gynaecology (segments).The funding will be used to enter these two areas. We will be adding 200 people for our paediatric section.”
“A long-term impact in the field of R&D will make newer innovations in the field of dermatology possible,“ said Darda.
Tata Capital Healthcare Fund, partner, Visalakshi Chandramouli said “After evaluating the opportunities in the market, adjusted for relative valuation, we concluded that we would be better served to invest in small and mid-sized businesses seeking growth capital, sharply focusing on key growing niche therapies. Brinton offered us that opportunity as we viewed it as a company promoted by a young entrepreneur whose family had roots in the pharma business.”
With this fresh capital inflow ,Brinton Pharmaceuticals is planning to expand its international operations in addition to betting big on fast-growing therapeutic segments such as paediatrics and gynaecology.